Search

for
Search:

GlossaryJAK-STAT pathway (Janus kinase-signal transducer and activator of transcription pathway)

transmits signals from cell surface to nucleus for gene expression

The JAK-STAT pathway, short for Janus kinase-signal transducer and activator of transcription pathway, is a chain of interactions between proteins in a cell that transmits signals from chemical signals outside the cell to the cell nucleus, resulting in DNA transcription and activity changes. This pathway is crucial for regulating immune function, cell growth, and development, and has been implicated in various diseases, including certain types of alopecia and cancers.

Related Terms

Sort by

Research

30 / 1000+ results

research Topical Metformin as a Novel Therapy for Alopecia Areata Due to Its Immunologic Effects

August 2023 in “Medical Hypotheses”

Metformin, usually used for diabetes, can also help treat hair loss from alopecia areata due to its ability to reduce inflammation and stimulate new hair growth.

research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis

223 citations, September 2018 in “Rheumatology”

JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.

Analyzing the Role of Tofacitinib in Treatment of Alopecia Areata: A Retrospective Analysis from a Tertiary Care Center of North India

research Analyzing the Role of Tofacitinib in Treatment of Alopecia Areata: A Retrospective Analysis from a Tertiary Care Center of North India

January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology”

Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.

research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata

August 2023 in “International journal of research in dermatology”

Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.

Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata

research Selective Janus Kinase 1 Inhibition Resolves Inflammation and Restores Hair Growth Offering a Viable Treatment Option for Alopecia Areata

4 citations, January 2023 in “Skin health and disease”

Blocking Janus kinase 1 helps stop inflammation and regrow hair, making it a good treatment for hair loss from alopecia areata.

research Regenerating the Skin: A Task for the Heterogeneous Stem Cell Pool and Surrounding Niche

133 citations, September 2013 in “Nature Reviews Molecular Cell Biology”

Different types of stem cells and their environments are key to skin repair and maintenance.

research Lokivetmab Improved Pruritus in a Dog With Cutaneous Epitheliotropic Lymphoma

2 citations, December 2021 in “Journal of Veterinary Medical Science”

Lokivetmab reduced itching in a dog with skin lymphoma.

research Baricitinib: From Rheumatoid Arthritis to COVID-19

42 citations, April 2021 in “Journal of clinical pharmacology”

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

In-Silico Study of Bioactive Compounds of Natural Materials as a JAK-Signal Transducer and Activator of Transcription Inhibitor for Anti-Alopecia

research In-Silico Study of Bioactive Compounds of Natural Materials as a JAK-Signal Transducer and Activator of Transcription Inhibitor for Anti-Alopecia

November 2017 in “Asian journal of pharmaceutical and clinical research”

Three compounds from Dadap leaves may help treat hair loss.

research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata

May 2023 in “International Journal of Trichology”

Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.

research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata

May 2023 in “International Journal of Trichology”

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

research Janus Kinase Inhibitors for Alopecia Areata: A Narrative Review

2 citations, June 2023 in “Indian journal of dermatology, venereology, and leprology”

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia

3 citations, February 2024 in “Journal of the American Academy of Dermatology”

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib

2 citations, May 2020 in “JAAD case reports”

Ruxolitinib can cause a delayed skin reaction on the nose.

research Adipose Tissue Remodeling via TSLP-Mediated IL-4/IL-13 Signaling: Implications for Atopic Dermatitis and Skin Barrier

June 2024 in “Journal of Allergy and Clinical Immunology”

TSLP affects atopic dermatitis by increasing sebum and reducing fat through IL-4/IL-13 signaling.

research Platelet-Rich Plasma in the Treatment of Alopecia Areata: A Retrospective Evaluation of 17 Patients

3 citations, April 2023 in “Dermatologica Sinica”

PRP treatment may help with alopecia areata, especially in newer cases.

research Forsythiasides: A Review of the Pharmacological Effects

2 citations, July 2022 in “Frontiers in Cardiovascular Medicine”

Forsythiasides have multiple health benefits but may cause pseudoallergic reactions, and more research is needed.

research A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo

25 citations, April 2019 in “Journal of The American Academy of Dermatology”

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

January 2023 in “Indian Dermatology Online Journal”

No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.

research The Emerging Role of Janus Kinase Inhibitors in the Treatment of Autoimmune and Inflammatory Diseases

70 citations, October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations, October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective

research Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective

8 citations, October 2022 in “Dermatology practical & conceptual”

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

research New Drugs Under Investigation for the Treatment of Alopecias

26 citations, January 2019 in “Expert Opinion on Investigational Drugs”

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

research Under Development JAK Inhibitors for Dermatologic Diseases

14 citations, January 2020 in “Mediterranean Journal of Rheumatology”

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.

research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation

1 citations, January 2023 in “Research Square (Research Square)”

A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.

research Janus Kinase Inhibitors in Dermatology: A Systematic Review

116 citations, February 2017 in “Journal of the American Academy of Dermatology”

JAK inhibitors help with skin conditions but need more research on dosing and safety.

research Janus Kinase Inhibitors in the Treatment of Alopecia Areata

2 citations, January 2023 in “Prague Medical Report”

JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.

research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review

February 2024 in “PloS one”

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

research JAK Inhibitors for Treatment of Alopecia Areata

63 citations, July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology”

JAK inhibitors can effectively reverse hair loss in people with alopecia areata.

research Janus Kinase Inhibitors For Alopecia Areata

12 citations, June 2023 in “JAMA network open”

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.